Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Cash from Financing Activities (2020 - 2022)

Historic Cash from Financing Activities for Atea Pharmaceuticals (AVIR) over the last 3 years, with Q3 2022 value amounting to $147000.0.

  • Atea Pharmaceuticals' Cash from Financing Activities fell 8150.94% to $147000.0 in Q3 2022 from the same period last year, while for Dec 2022 it was $370000.0, marking a year-over-year decrease of 7474.4%. This contributed to the annual value of $267000.0 for FY2024, which is 389.11% up from last year.
  • Latest data reveals that Atea Pharmaceuticals reported Cash from Financing Activities of $147000.0 as of Q3 2022, which was down 8150.94% from $223000.0 recorded in Q1 2022.
  • Atea Pharmaceuticals' 5-year Cash from Financing Activities high stood at $426.2 million for Q4 2020, and its period low was -$913000.0 during Q3 2020.
  • For the 3-year period, Atea Pharmaceuticals' Cash from Financing Activities averaged around $53.4 million, with its median value being $185000.0 (2022).
  • Examining YoY changes over the last 5 years, Atea Pharmaceuticals' Cash from Financing Activities showed a top increase of 795000.0% in 2021 and a maximum decrease of 9996.67% in 2021.
  • Quarter analysis of 3 years shows Atea Pharmaceuticals' Cash from Financing Activities stood at $426.2 million in 2020, then tumbled by 99.97% to $142000.0 in 2021, then grew by 3.52% to $147000.0 in 2022.
  • Its last three reported values are $147000.0 in Q3 2022, $223000.0 for Q1 2022, and $142000.0 during Q4 2021.